The downside of semaglutides
GLP-1-based therapies for obesity have been transformational. The benefits are undeniable, and the risks for most people are negligible. These drugs belong in the class with anti-hypertensives and statins. Who could complain? Here's one doc who was an initial enthusiast, but who has cooled: “The truth is, most patients don't stay on anti-obesity medications -- I see it in my practice every day. Research shows that three-quarters of patients stop GLP-1 medications within 2 years , many within months. Reasons for discontinuation include cost, side effects, and supply shortages. But one of the most common reasons is that patients simply don't want to take a weight loss medication indefinitely. Many believe they can "beat the system," use them briefly, change their lifestyle, and stop taking them without regaining weight. “Unfortunately, they can't. Clinical trials of semaglutide and tirzepatide show that the average patient regains two-thirds of the weight lo...